65992 Federal Register / Vol. 66, No. 246 / Friday, December 21, 2001 / Notices

contesting it, and the proposed

amendment to the record.

RECORD SOURCE CATEGORIES:

Individuals or entities having

information pertinent to the

adjudication of compensation claims,

including but not limited to: Injured

individuals; personal representatives of

deceased individuals; eligible claimants;

family members; physicians and other

medical professionals, hospitals, and

clinics; insurers, employers, and their

agents and representatives.

SYSTEMS EXEMPTED FROM CERTAIN PROVISIONS

OF THE ACT:

None.

[FR Doc. 01–31461 Filed 12–18–01; 12:28

pm]

BILLING CODE 4410–12–P

DEPARTMENT OF JUSTICE

Antitrust Division

United States v. Premdor Inc. et al.

A Complaint, Hold Separate

Stipulation and Order, proposed Final

Judgment, and Competitive Impact

Statement were filed with the United

States District Court for the District of

Columbia, in a civil antitrust case,

United States v. Premdor Inc., Premdor

U.S. Holdings, Inc., International Paper

Company, and Masonite Corporation,

Civ. Action No. 1:01CV01696. By

August 28, 2001, the United States

published a notice in the Washington

Post and the Federal Register, seeking

public comments on the proposed

settlement, in accord with the Antitrust

Procedures and Penalties Act, 15 U.S.C.

16(b) through (h). The 60 day comment

period expired on October 29, 2001. Due

to the unanticipated disruption of mail

service to the U.S. Department of

Justice, the United States requests that

anyone who submitted a comment

before the expiration of the comment

period resubmit the comment by

facsimile or e-mail to J. Robert Kramer

II, Chief, Litigation II Section, Antitrust

Division, U.S. Department of Justice,

1401 H Street, NW., Suite 3000,

Washington, DC 20530 (facsimile: (202)

307–5802; e-mail:

comments.lit2@usdoj.gov; telephone:

(202) 307–0924). Comments should be

resubmitted by facsimile or e-mail

within 15 days of the date of this notice.

Constance K. Robinson,

Director of Operations & Merger Enforcement.

[FR Doc. 01–31477 Filed 12–20–01; 8:45 am]

BILLING CODE 4410–11–M

DEPARTMENT OF JUSTICE

Antitrust Division

United States v. 3d Systems Corp. and

DTM Corp.

A Complaint, proposed Final

Judgment, and Competitive Impact

Statement were filed with the United

States District Court for the District of

Columbia, in a civil antitrust case,

United States v. 3D Systems

Corporation and DTM Corporation, Civ.

Action No. 1:01CV01237. By September

26, 2001, the United States published a

notice in the Washington Post and the

Federal Register, seeking public

comments on the proposed settlement,

in accord with the Antitrust Procedures

and Penalties Act, 15 U.S.C. 16(b)

through (h). The 60-day comment

period expired on November 26, 2001.

Due to the unanticipated disruption of

mail service to the U.S. Department of

Justice, the United States requests that

anyone who submitted a comment

before the expiration of the comment

period resubmit the comment by

facsimile or e-mail to J. Robert Kramer

II, Chief, Litigation II Section, Antitrust

Division, U.S. Department of Justice,

1401 H Street, NW., Suite 3000,

Washington, DC 20530 (facsimile: (202)

307–5802; e-mail:

comments.lit2@usdoj.gov; telephone:

(202) 307–0924). Comments should be

resubmitted by facsimile or e-mail

within 15 days of the date of this notice.

Constance K. Robinson,

Director of Operations & Merger Enforcement.

[FR Doc. 01–31478 Filed 12–20–01; 8:45 am]

BILLING CODE 4410–11–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled

Substances; Notice of Application

Pursuant to section 1301.33(a) of Title

21 of the Code of Federal Regulations

(CFR), this is notice that on March 8,

2001, American Radiolabeled Chemical,

Inc., 11624 Bowling Green Drive, St.

Louis, Missouri 63146, made

application by renewal and by letter

dated May 2, 2001, to the Drug

Enforcement Administration (DEA) for

registration as a bulk manufacturer of

the basic classes of controlled

substances listed below:

Drug Schedule

Gamma hydroxybutyric acid

(2010).

I

Lysergic acid diethylamide (7315) I

Drug Schedule

Dimethyltryptamine (7435) ........... I

Dihydromophine (9145) ................ I

Phencyclidine (7471) .................... II

Cocaine (9041) ............................. II

Codeine (9050) ............................. II

Hydromorphone (9150) ................ II

Oxycodone (9143) ........................ II

Thebaine (9333) ........................... II

Benzoylecgonine (9180) ............... II

Meperidine (9230) ........................ II

Metazocine (9240) ........................ II

Morphine (9300) ........................... II

Oxymorphone (9652) ................... II

The firm plans to bulk manufacture

small quantities of the listed controlled

substances as radiolabeled compounds.

Any other such applicant and any

person who is presently registered with

DEA to manufacture such substance

may file comments or objections to the

issuance of the proposed registration.

Any such comments or objections

may be addressed, in quintuplicate, to

the Deputy Assistant Administrator,

Office of Diversion Control, Drug

Enforcement Administration, United

States Department of Justice,

Washington, DC 20537, Attention: DEA

Federal Register Representative (CCR),

and must be filed no later than February

19, 2002.

Dated: November 15, 2001.

Laura M. Nagel,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 01–31408 Filed 12–20–01; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled

Substances; Notice of Application

Pursuant to section 1301.33(a) of Title

21 of the Code of Federal Regulations

(CFR), this is notice that on September

11, 2001, Genesis 1:29 Corporation, P.O.

Box 2175, 133 Bond Avenue, Petaluma,

California 94654, made application to

the Drug Enforcement Administration

(DEA) for registration as a bulk

manufacturer of the basis classes of

controlled substances listed below:

Drug Schedule

Marihuana (7360) ........................... I

Tetrahydrocannabinols (7370) ........ I

The firm plans to cultivate marihuana

to supply physician’s patients within

the State of California.